ES2294696T3 - Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene. - Google Patents

Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene. Download PDF

Info

Publication number
ES2294696T3
ES2294696T3 ES05731028T ES05731028T ES2294696T3 ES 2294696 T3 ES2294696 T3 ES 2294696T3 ES 05731028 T ES05731028 T ES 05731028T ES 05731028 T ES05731028 T ES 05731028T ES 2294696 T3 ES2294696 T3 ES 2294696T3
Authority
ES
Spain
Prior art keywords
albumin
solution
nanofiltration
aqueous
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05731028T
Other languages
English (en)
Spanish (es)
Inventor
Paul Boulange
Sami Chtourou
Stephane Boyer
Roland Schmitthaeusler
Bruno Padrazzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34834103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2294696(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LFB SA filed Critical LFB SA
Application granted granted Critical
Publication of ES2294696T3 publication Critical patent/ES2294696T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES05731028T 2004-02-27 2005-02-23 Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene. Expired - Lifetime ES2294696T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0402001A FR2866890B1 (fr) 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
FR0402001 2004-02-27

Publications (1)

Publication Number Publication Date
ES2294696T3 true ES2294696T3 (es) 2008-04-01

Family

ID=34834103

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05731028T Expired - Lifetime ES2294696T3 (es) 2004-02-27 2005-02-23 Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene.

Country Status (16)

Country Link
US (3) US20070161122A1 (enExample)
EP (1) EP1718673B1 (enExample)
JP (2) JP4979571B2 (enExample)
AT (1) ATE373014T1 (enExample)
AU (1) AU2005223418B2 (enExample)
BR (1) BRPI0507886A (enExample)
CA (1) CA2557174C (enExample)
CY (1) CY1107082T1 (enExample)
DE (1) DE602005002461T2 (enExample)
DK (1) DK1718673T3 (enExample)
ES (1) ES2294696T3 (enExample)
FR (1) FR2866890B1 (enExample)
IL (1) IL177286A (enExample)
PL (1) PL1718673T3 (enExample)
PT (1) PT1718673E (enExample)
WO (1) WO2005090402A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
FR3004451B1 (fr) * 2013-04-11 2015-12-11 Lab Francais Du Fractionnement Procede de preparation d'une solution de proteine c viralement securisee par une double etape de nanofiltration
EP3119412A1 (en) * 2014-03-21 2017-01-25 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
FR3040882A1 (fr) * 2015-09-10 2017-03-17 Lab Francais Du Fractionnement Composition liquide d'albumine humaine a usage therapeutique
US11640846B2 (en) * 2020-01-30 2023-05-02 Fresenius Medical Care Holdings, Inc. Techniques for modelling and optimizing dialysis toxin displacer compounds
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH06279296A (ja) * 1993-03-25 1994-10-04 Asahi Chem Ind Co Ltd 血漿分画製剤中から蛋白質会合物の除去方法
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DK1329460T3 (da) * 2000-10-24 2006-07-31 Chemo Sero Therapeut Res Inst Fremgangsmåde til monomerisering af polymerer af humant serum albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
JPWO2004089402A1 (ja) * 2003-04-09 2006-07-06 財団法人化学及血清療法研究所 アルブミン製剤の製造方法
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Also Published As

Publication number Publication date
AU2005223418B2 (en) 2008-12-18
US10562957B2 (en) 2020-02-18
US20070161122A1 (en) 2007-07-12
DK1718673T3 (da) 2008-01-14
FR2866890A1 (fr) 2005-09-02
DE602005002461D1 (de) 2007-10-25
AU2005223418A1 (en) 2005-09-29
CA2557174C (fr) 2013-04-30
JP2012102115A (ja) 2012-05-31
DE602005002461T2 (de) 2008-06-12
US20150152162A1 (en) 2015-06-04
CY1107082T1 (el) 2012-10-24
FR2866890B1 (fr) 2008-04-04
CA2557174A1 (fr) 2005-09-29
PT1718673E (pt) 2007-12-13
US9611311B2 (en) 2017-04-04
JP2007535495A (ja) 2007-12-06
EP1718673B1 (fr) 2007-09-12
IL177286A0 (en) 2006-12-10
IL177286A (en) 2012-08-30
ATE373014T1 (de) 2007-09-15
EP1718673A1 (fr) 2006-11-08
JP4979571B2 (ja) 2012-07-18
PL1718673T3 (pl) 2008-03-31
US20170166626A1 (en) 2017-06-15
WO2005090402A1 (fr) 2005-09-29
BRPI0507886A (pt) 2007-08-07

Similar Documents

Publication Publication Date Title
US10562957B2 (en) Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same
ES2553385T3 (es) Proceso para preparar una composición de inmunoglobulina
ES2527915T3 (es) Producto de inmunoglobulina G (IgG) líquido
ES2229784T3 (es) Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina.
CN102459331B (zh) 生产用于皮下使用的高度浓缩的免疫球蛋白制品的方法
ES2767132T3 (es) Extracto de plaquetas inactivado viral, uso y preparación del mismo
ES2202613T3 (es) Procedimiento de esterilizacion final de productos biologicos.
ES2641042T3 (es) Procedimiento para la fabricación de un fármaco proteínico
ES2517540T3 (es) Procedimiento de preparación de concentrado de inmunoglobulinas G (IgG) empobrecido en anticuerpos anti-A y anti-B
ES2564627T3 (es) Composición de alfa-1-antitripsina
RU2424822C2 (ru) Способ получения высокоэффективного человеческого альбумина для применения в детоксикационной терапии
ES2590045T3 (es) Procedimiento para obtener una composición de IgG mediante tratamiento térmico
ES2213760T3 (es) Preparacion de globulina de suero inmunizante inyectable por via intravenosa con virus inactivado.
ES2689333T3 (es) Método de eliminación de contaminantes
ES2483151T3 (es) Procedimiento de preparación de un concentrado de von Willebrand (fvw) mediante cromatografía y concentrado de fvw susceptible de ser así obtenido
ES2305272T3 (es) Procedimiento de purificacion a gran escala de globulina gc, producto obtenido por el mismo y su uso en medicina.
US20140163101A1 (en) Caprylate viral deactivation
HU221239B1 (en) Method of inactivating viruses in proteins
RU2257916C1 (ru) Препарат, содержащий иммуноглобулин против лихорадки марбург из сыворотки крови лошадей жидкий (иммуноглобулин лошадиный марбург)
JPS6030292B2 (ja) 人顆粒球の分化増殖を促進する加熱処理ｈｇｉｇｐ及びｈｇｉｇｐの加熱処理法
BR102016022107B1 (pt) Processo para preparação de uma solução de imunoglobulinas
BR102016022107A2 (pt) Processo de preparação de imunoglobulinas
Marzo et al. Hyperimmune immunoglobulins: Manufacturing technologies and safety procedures
TW201811815A (zh) 製備免疫球蛋白溶液的方法及其用途
HK1151044B (en) Process for manufacturing immunoglobulins for intravenous administration and other immunoglobulin-like products